In vitro studies in an erythroid progenitor cell line and primary CD34+ cells demonstrated that the EPORW439* variant conferred a strong proliferative advantage to therapeutically modified erythroid progenitors, establishing a strategy to amplify the therapeutic benefit of otherwise limited in vivo HSPC gene editing fo...
Akshara Sakunthala Velmurugan, K. Paschoudi, Jack A. Queenan et al.· bioRxiv· 0 citations
Hemoglobinopathies provide the first clinically validated delivery model for CRISPR therapeutics, and offers a donor-independent alternative to allogeneic hematopoietic stem-cell transplantation without graft rejection or graft-versus-host disease.
Data support initiation of a first-in-human phase I trial of CRISPR_SCD001 for sickle patients presenting with severe pathology, and generates a clinical-grade, cryopreserved CD34+ cell product that corrects the sickle mutation, restores anti-sickling hemoglobins, and meets pre-clinical safety criteria.
M. DeWitt, Beatriz Campo-Fernández, Sohini Roy et al.· Molecular Therapy· 0 citations
Hemoglobinopathies are the most common inherited anemias worldwide. While most carriers are asymptomatic or mildly affected, severe forms of α-thalassemia, including severe hemoglobin H (HbH) disease and surviving individuals with Hb Bart’s hydrops fetalis syndrome (BHFS), require lifelong transfusion support or stem c...
Si-Yu Liu, A. Ejaz, Andrew J. King et al.· Nature Genetics· 0 citations
A variety of research is synthesized, examining the therapeutic potential of stem cell therapy and CRISPR/Cas technology in the treatment of thalassemia, highlighting the use of stem cell therapy and CRISPR/Cas gene editing technology as alternative treatment options.
Shreya Nair· International Journal For Mu...· 0 citations
PASSIGE (prime editing-assisted site-specific integrase gene editing) is reported in CD34+ HSPCs, developing a more broadly applicable, double-strand break-independent complementary DNA insertion strategy with the potential to address a large proportion of alleles causing GATA2 deficiency.
J. H. Wolff, T. W. Skov, S. R. Dorset et al.· Science Translational Medici...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.